A. Stewart

发表

Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.

Jill M. Wetter, J. Brioni, S. Baker, 2006, Bioorganic & medicinal chemistry letters.

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors.

A. Gomtsyan, R. Snyder, Chih-Hung Lee, 2005, Bioorganic & medicinal chemistry.

Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels

G. Dubé, J. Brioni, S. Baker, 2005, Pain.

Preclinical and Clinical Activity of Zileuton and A‐78773

R. Hansen, D. W. Brooks, G. Carter, 1993, Annals of the New York Academy of Sciences.

Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

R. D. Dyer, P. Young, J. Summers, 1988, Journal of medicinal chemistry.

Orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

R. D. Dyer, P. Young, J. Summers, 1988, Journal of medicinal chemistry.

Stereoselective Metabolism of the 5‐Lipoxygenase Inhibitor A‐78773

L. Dubé, R. Hansen, J. Bouska, 1994, Annals of the New York Academy of Sciences.

(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.

J. Bouska, G. Carter, P. Bhatia, 1995, Journal of medicinal chemistry.

Asymmetric synthesis of (R)-N-3-butyn-2-yl-N-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitors

C. Brooks, T. Kolasa, A. Stewart, 1996 .

Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.

J. Bouska, D. W. Brooks, G. Carter, 1995, The Journal of pharmacology and experimental therapeutics.

Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.

L. Kifle, K. Marsh, G. Zhu, 2001, Journal of medicinal chemistry.

Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.

C. Goodfellow, G. Carter, J. Bouska, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets

J. Brioni, A. Saraf, J. Rogers, 2007, Neuropharmacology.

Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D4 receptor agonists.

M. Nakane, J. Brioni, R. Moreland, 2005, Bioorganic & medicinal chemistry.

2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist

D. Donnelly-roberts, Jill M. Wetter, M. Nakane, 2005, Neuropharmacology.

Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists.

D. Donnelly-roberts, M. Nakane, J. Brioni, 2004, Bioorganic & medicinal chemistry.

Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats.

J. Brioni, S. Baker, R. Moreland, 2008, European journal of pharmacology.

[3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.

J. Brioni, R. Moreland, R. Chang, 2004, European journal of pharmacology.

A-78773: a selective, potent 5-lipoxygenase inhibitor.

P. Young, J. Bouska, D. W. Brooks, 1993, Journal of lipid mediators.

Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand.

D. Donnelly-roberts, M. Nakane, J. Brioni, 2004, Bioorganic & medicinal chemistry letters.

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat

T. Brennan, J. Sullivan, M. Williams, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.

D. Donnelly-roberts, Jill M. Wetter, G. Gintant, 2006, Journal of medicinal chemistry.

Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.

Meena Patel, M. Nakane, J. Brioni, 2005, Journal of medicinal chemistry.

C-glycosidation of pyridyl thioglycosides

Robert M. Williams, A. Stewart, 1985 .

Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.

Scott P. Brown, S. Muchmore, J. Brioni, 2009, Journal of medicinal chemistry.

ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor

G. Carter, S. Surapaneni, K. Marsh, 2004, Journal of Pharmacology and Experimental Therapeutics.

C-glycosidation of pyridyl thioglycosides

Robert M. Williams, A. Stewart, 1983 .

Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.

L. Kifle, C. McCarty, K. Marsh, 2001, Journal of medicinal chemistry.

A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.

A. Hancock, A. Stewart, T. Esbenshade, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of pteridine and pyrazolopyrimidine based adenosine kinase inhibitors.

A. Gomtsyan, Chih-Hung Lee, S. Bhagwat, 2004, Bioorganic & medicinal chemistry letters.

4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.

A. Gomtsyan, S. Muchmore, Chih-Hung Lee, 2007, Bioorganic & medicinal chemistry.

Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor..

M. Williams, S. Bhagwat, M. Jarvis, 2001, Journal of medicinal chemistry.

Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor

Chih-Hung Lee, M. Jarvis, J. Mikusa, 2002, Pain.

Pyridopyrimidine analogues as novel adenosine kinase inhibitors.

A. Gomtsyan, S. Muchmore, M. Jarvis, 2001, Bioorganic & medicinal chemistry letters.

The preparation and wittig condensations of C-4 thiazole phosphonium methylides

David R. Williams, A. Stewart, D. Brooks, 1996 .

Design of inhibitors of leukotriene biosynthesis and their therapeutic potential

J. Bouska, G. Carter, R. Harris, 1998 .

N,O-Bis(phenoxycarbonyl)hydroxylamine: a new reagent for the direct synthesis of substituted N-hydroxyureas

D. W. Brooks, A. Stewart, 1992 .

Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

R. Maki, P. Young, J. Summers, 1997, Journal of medicinal chemistry.

Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.

R. D. Dyer, J. Summers, H. Mazdiyasni, 1990, Journal of medicinal chemistry.

Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

Gram scale synthesis of the glucuronide metabolite of ABT-724.

S. Wagaw, Kenneth M. Engstrom, A. Stewart, 2006, The Journal of organic chemistry.

Adenosine kinase inhibitors: polar 7-substitutent of pyridopyrimidine derivatives improving their locomotor selectivity.

Chih-Hung Lee, Changcheng Zhu, M. Jarvis, 2003, Bioorganic & medicinal chemistry letters.

Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors.

S. Bhagwat, E. Bayburt, M. Jarvis, 2001, Bioorganic & medicinal chemistry letters.

PII: S0304-3959(01)00435-3

Chih-Hung Lee, M. Jarvis, J. Mikusa, 2002 .

Synthesis of (1-aryl-1-alkylethyl)alkoxyamines

A. Stewart, Jonathan G. Martin, 1989 .

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A‐841720, a novel non‐competitive mGluR1 receptor antagonist

G. Fox, S. Baker, M. Mezler, 2006, British journal of pharmacology.

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and resolution of 2-(cyclohexyl-4-(2-quinolylmethoxy)phenyl)methoxyiminopropionic acid, leukotriene biosynthesis inhibitors

T. Kolasa, A. Stewart, D. Gunn, 1996 .

Synthesis and structure-activity relationships of 5-heteroatom-substituted pyridopyrimidines as adenosine kinase inhibitors.

A. Gomtsyan, Chih-Hung Lee, S. Bhagwat, 2003, European journal of medicinal chemistry.

Synthesis and Structure—Activity Relationships of 5-Heteroatom-Substituted Pyridopyrimidines as Adenosine Kinase Inhibitors.

A. Gomtsyan, Chih-Hung Lee, S. Bhagwat, 2003 .

Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation

S. Otte, J. Brioni, M. Decker, 2006, Neuropharmacology.

Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R).

M. Jarvis, X. Beebe, V. Scott, 2008, Bioorganic & medicinal chemistry letters.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Journal of medicinal chemistry.

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Journal of medicinal chemistry.

A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats.

A. Swensen, T. Neelands, T. Vortherms, 2012, Biochemical pharmacology.

Design of adenosine kinase inhibitors from the NMR-based screening of fragments.

Jean M. Severin, E A Kowaluk, P. Hajduk, 2000, Journal of medicinal chemistry.

Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists.

J. Brioni, R. Moreland, P. Honore, 2007, Bioorganic & medicinal chemistry letters.

Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes.

Jean M. Severin, A. Gomtsyan, S. Muchmore, 2006, Journal of Medicinal Chemistry.

COX-2 Inhibitors and Leukotriene Modulators

R. Bell, A. Stewart, R. Harris, 2003 .

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

N,O-Bis(phenoxycarbonyl)hydroxylamine: A New Reagent for the Direct Synthesis of Substituted N-hydroxyureas.

D. W. Brooks, A. Stewart, 1993 .

Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.

Jill M. Wetter, R. Henry, A. Swensen, 2012, Bioorganic & medicinal chemistry.

ABT-963, A Highly Potent and Selective Disubstituted Pyridazinone COX-2 Inhibitor

G. Carter, S. Surapaneni, M. Jarvis, 2004 .